The Role of the CDSCO: India's Central Drug Regulator

The Central Drugs Standard Control Organization, operating under India's Ministry of Health and Family Welfare, functions as the country's national regulatory authority for pharmaceuticals and medical devices. It is the body responsible for approving new drugs before they can be marketed in India, regulating clinical trials, setting and enforcing manufacturing standards, and coordinating drug regulation with the State Drug Licensing Authorities that handle manufacturing licenses and local enforcement within each state.

One of the CDSCO's central responsibilities is new drug approval — reviewing the safety, efficacy, and quality data submitted by manufacturers before permitting a medicine to be sold in the country. For generic medicines specifically, this includes review of bioequivalence study data comparing the proposed generic against the approved reference product, alongside manufacturing quality documentation demonstrating that the facility producing the medicine operates in compliance with Good Manufacturing Practice requirements set out in Schedule M of the Drugs and Cosmetics Rules.

The organization also plays a central role in pharmacovigilance — the ongoing monitoring of medicine safety after a product has already reached the market. Through India's national pharmacovigilance program, adverse event reports from healthcare providers and patients are collected, analyzed, and, where necessary, acted upon through updated labeling requirements or, in rare cases, market withdrawal. This post-approval monitoring is a critical complement to pre-approval testing, because certain rare safety signals only become statistically detectable once a medicine has been used by a very large population over an extended period.

The CDSCO additionally oversees the licensing and inspection of manufacturing facilities in coordination with state authorities, sets and updates the technical standards published in the Indian Pharmacopoeia that define acceptable purity and quality specifications for individual medicines, and represents India in international regulatory harmonization discussions with bodies such as the World Health Organization. This international engagement matters increasingly as Indian-manufactured medicines are exported to a growing number of countries, each with its own regulatory expectations that Indian standards must remain compatible with.

For anyone sourcing medicine manufactured in India, understanding the CDSCO's role clarifies an important point: domestic regulatory oversight in India is not a lesser or informal system running in parallel to international standards like WHO-GMP or USFDA approval — it is the foundational national framework that every facility must satisfy first, before it can even be considered for the additional layer of international certification that allows it to export with confidence to markets around the world.